Neuropathic Chronic Pain

Okyo Pharma has announced that screening and recruitment has been initiated for a phase 2 trial of OK-101 to treat neuropathic corneal pain, with plans to enroll 48 patients, according to a company press release.

Medical cannabis use for chronic pain may confer increased risk for de novo arrhythmia compared with nonuse or other treatments for chronic pain, researchers in Denmark reported.